A5033699674- Clostridium difficile and Clostridium perfringens research
- Hepatitis C virus research
- Gut microbiota and health
- Chronic Lymphocytic Leukemia Research
- Microscopic Colitis
- Cytomegalovirus and herpesvirus research
- Helicobacter pylori-related gastroenterology studies
- Hepatitis B Virus Studies
- COVID-19 Clinical Research Studies
- Antimicrobial Resistance in Staphylococcus
- Antifungal resistance and susceptibility
- COVID-19 and healthcare impacts
- HIV/AIDS drug development and treatment
- Bacterial Identification and Susceptibility Testing
- Polyomavirus and related diseases
- Colorectal Cancer Treatments and Studies
- Nosocomial Infections in ICU
- Monoclonal and Polyclonal Antibodies Research
- Healthcare cost, quality, practices
- Alcohol Consumption and Health Effects
- Pneumocystis jirovecii pneumonia detection and treatment
- Renal Transplantation Outcomes and Treatments
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Respiratory viral infections research
The University of Texas MD Anderson Cancer Center
2017-2024
INTRODUCTION: Data are scarce regarding the virologic impact and safety of immune checkpoint inhibitors (ICI) in patients with chronic hepatitis C virus (HCV) infection. We examined ICI HCV-infected solid tumors their safety. METHODS: tumor treated at our institution between April 26, 2016, January 5, 2022, were enrolled a prospective observational study. The primary outcomes ICI-induced changes HCV viremia (HCV inhibition reactivation) ICI. RESULTS: 52 consecutive Most men (41; 79%), White...
Patients with cancer are particularly vulnerable to Clostridioides difficile infection (CDI). Guidelines recommend a two-step diagnostic algorithm differentiate carriers from CDI; however, there limited data for this approach while including other confounding risk factors diarrhea such as radiation, cytotoxic chemotherapy, and adoptive cell based therapies.We conducted prospective, non-interventional, single center, cohort study of patients acute C. difficile, identified in stools by nucleic...
Antibiotic use is a risk factor for Clostridioides difficile infection (CDI). Few studies have correlated of prior antibiotic classes with CDI, microbiome composition, and disease severity in patients cancer. We hypothesized that previous exposure fecal composition at time presentation are factors severe CDI cancer.This non-interventional, prospective, cohort study examined 200 cancer who had their first episode or recurrence CDI. C. was identified using nucleic acid amplification testing....
Peritoneal histoplasmosis is a rare entity with few cases reported in the literature. We present case of isolated acute peritoneal that mimicked an advanced ovarian malignancy patient undergoing antitumor necrosis factor therapy for rheumatoid arthritis. also reviewed literature on Histoplasma peritonitis.
The prevalence of chronic hepatitis C virus (HCV) infection in the United States is ≤1%. Universal HCV screening recommended nationwide. Here we describe our experience implementing universal at a cancer center.
Abstract Background An increasing number of observational studies have reported the persistence symptoms following recovery from acute COVID-19 disease. The long-term consequences are not fully understood and there is no clear consensus on definition post-acute sequelae SARS-CoV-2 infection (PASC). prevalence PASC widely varies 10% up to 87%. purpose this study assess in cancer patients recovery. Methods We assessed at MD Anderson Cancer Center who were diagnosed with disease between March...
In this international multicenter study we aimed to determine the independent risk factors associated with increased 30-day mortality and impact of novel treatment modalities in a large group cancer non-cancer patients COVID-19 from multiple countries.We retrospectively collected de-identified data on cohort diagnosed between January November 2020, 16 centers.We analyzed 3966 confirmed patients, 1115 2851 patients. Cancer were more likely be pancytopenic, have smoking history, pulmonary...
Abstract Background The detection of C. difficile (CDI) by nucleic acid amplification test (NAAT) with negative toxin enzyme immunoassay (EIA-) is difficult to interpret in cancer patients. Markers that differentiate true infection from colonization, and are associated clinical outcomes needed. We hypothesized the microbiome composition inflammatory fecal markers EIA- patients differed those who EIA+ were disease severity recurrence. Methods studied (16s rRNA, V3) 147 CDI diagnosed a...
Objective There is no prospective data on 8 weeks of direct-acting antivirals (DAA) therapy with glecaprevir/pibrentasvir (GLE/PIB) or ledipasvir/sofosbuvir (LDV/SOF) in hepatitis C virus (HCV)-infected patients different types malignancies. This study evaluated the efficacy and safety DAA cancer chronic HCV infection. Methods Patients treated DAAs at our center during 2014–2021 were included a observational study. Efficacy (sustained virologic response 12 weeks; SVR12) [adverse events...
3142 Background: Most cancer patients with chronic hepatitis C virus (HCV) infection are excluded from clinical trials (CCTs). The use of direct-acting antivirals (DAAs) to eradicate HCV and allow access CCTs in HCV-infected has not been studied. We aimed evaluate the efficacy safety DAA treatment increase hematologic malignancies (HM). Methods: HM seen at MD Anderson Cancer Center between 01/01/2016 01/31/2023 were enrolled a prospective observational study. Those initially then treated...
Abstract Background Patients with cancer are at an increased risk for C. difficile infection (CDI). A two-step approach a Nucleic Acid Amplification Test (NAAT) followed by enzyme immunoassay (EIA) increases diagnostic sensitivity and specificity can be used to guide antibiotic therapy. We retrospectively investigated the relative performance of in patients solid tumors (ST), hematologic malignancies (HS), hematopoietic stem cell transplant recipients (HSCT). Methods identified 204 positive...
Abstract Background Cancer patients are at increased risk for Clostridium difficile infection (CDI) due to frequent health care contact, chemotherapy, use of antibiotics, and immunosuppression. Distinct ribotypes associated with CDI adverse outcomes. Ribotypes 14-020 the predominant in many hospitals. We examined contribution C. severity, response therapy outcomes this population. Methods Demographic clinical data were collected from 90 cancer a first episode or recurrence identified by...
Abstract Background Cancer patients are at an increased risk for C. difficile infection (CDI) which is often identified along with other enteropathogens. The impact of co-infections on outcomes has not been established in this population. We compared the factors and clinical characteristics CDI monoinfection (CDIM) coinfected bacterial (CDIB) or viral (CDIV) Methods Adult presenting primary recurrent (n = 88) a two-step GI multiplex assay (Biofire) followed by toxin A/B EIA, were classified...
Abstract Background The diagnosis of C. difficile infection (CDI) relies on using a nucleic acid amplification test (NAAT) followed by confirmatory toxin enzyme immunoassay (EIA). This study examined the utility fecal biomarkers and bacterial quantity (BQ) in differentiating patients with true (NAAT+/EIA+) from colonization (NAAT+/EIA-) context ribotypes. Methods We studied 136 diarrhea CDI identified NAAT stools for which A, B, EIA was performed. Fecal IL-8, IL-1β, calprotectin, lactoferrin...
Abstract Background Antibiotic use is a risk factor for CDI. Few studies have correlated of prior antibiotics with CDI severity in cancer patients. This study identified clinical and microbiology factors associated severe patients cancer. We hypothesized that previous antibiotic exposure microbiome composition at time presentation, are disease Methods non-interventional, prospective, single-center cohort examined who had their first episode or recurrence between Oct 27, 2016 Jul 1, 2019. C....
Abstract Background Given the limited collaborative international studies that evaluated COVID-19 in patients with cancer comparison to without cancer, we aimed determine independent risk factors associated increased 30-day mortality and impact of novel treatment modalities a large group non-cancer from multiple countries. Methods We retrospectively collected de-identified data on diagnosed between January November 2020, at 16 centers Asia, Australia, Europe, North America, South America. A...